ENDRA Life Sciences (NDRA) Expected to Announce Quarterly Earnings on Friday

ENDRA Life Sciences (NASDAQ:NDRA) is expected to be releasing its Q3 2026 results on Friday, November 13th. Analysts expect ENDRA Life Sciences to announce earnings of ($0.84) per share and revenue of $0.10 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its earnings results on Friday, August 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.21. On average, analysts expect ENDRA Life Sciences to post ($4.11) EPS for the current fiscal year and ($3.04) EPS for the next fiscal year.

ENDRA Life Sciences Stock Down 0.7%

NASDAQ:NDRA opened at $4.74 on Thursday. ENDRA Life Sciences has a one year low of $2.96 and a one year high of $6.95. The firm’s fifty day moving average is $5.41 and its two-hundred day moving average is $4.81.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, November 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $25.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc. (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic tools for tissue characterization. The company’s lead technology is Thermo-Acoustic Enhanced Ultrasound (TAEUS), which is designed to enhance conventional ultrasound systems with additional information about tissue properties. ENDRA is initially applying TAEUS to the assessment of liver disease, including the detection and measurement of liver fat associated with conditions such as nonalcoholic fatty liver disease.